Evidence map›Paper›PMID 32899009›Full record

ArticleMedicine2020

Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.

Gabriella d'Ettorre, Gregorio Recchia, Marco Ridolfi, Guido Siccardi, Claudia Pinacchio, Giuseppe Pietro Innocenti, Letizia Santinelli, Federica Frasca, Camilla Bitossi, Giancarlo Ceccarelli and 4 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
0.5field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021
    Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Clinical outcome of patients with HIV/SARS-COV-2 co-infection.Medical journal, Armed Forces India · 2022
    Article
  11. Article
  12. Article
  13. Distribution ofMicroorganisms · 2022
    Article
  14. HIV and COVID-19: review of clinical course and outcomes.HIV research & clinical practice · 2021
    Article
  15. HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Gabriella d'EttorreDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Gregorio RecchiaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Marco RidolfiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Guido SiccardiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Claudia PinacchioDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Giuseppe Pietro InnocentiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Letizia SantinelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Federica FrascaLaboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.
Camilla BitossiLaboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.
Giancarlo CeccarelliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Cristian BorrazzoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
Guido AntonelliLaboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.
Carolina ScagnolariLaboratory of Virology, Department of Molecular Medicine, affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University.
Claudio Maria MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155.
S.P.E.C.I.E.S. · USIstituto Pasteur · ITPoliclinico Umberto I · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleComplex immune dysregulation in interferon (IFN) and T cell response has been observed in human immunodeficiency virus (HIV-1)-infected patients as well as in coronavirus disease-2019 (COVID-19) patients. However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2. Hence, this study aims to compare type I IFN response and T cell activation levels between a SARS-CoV-2/HIV-1-coinfected female patient and age-matched HIV-1-positive or uninfected women. PATIENT CONCERNS: A 52-year-old woman diagnosed with SARS-CoV-2/HIV-1 coinfection, ten HIV-1-positive women and five age-matched-healthy individuals were enrolled in this study. DIAGNOSES: SARS-CoV-2 infection caused severe pneumonia in the second week of illness in HIV-1-positive patient under protease inhibitors. Chest high-resolution computed tomography images of the SARS-CoV-2/HIV-1-coinfected patient showed bilateral ground-glass opacities.

interventionsSARS-CoV-2/HIV-1-coinfected female patient under darunavir/cobicistat regimen received a 7-days hydroxychloroquine therapy. Analysis of IFNα/β mRNA levels and CD4 and CD8 T cell (CD38, human leukocyte antigen-DR [HLA-DR], CD38 HLA-DR) frequencies were performed by RT/real-time PCR assays and flow cytometry, respectively. Median relative difference (MRD) was calculated for each immunological variable. For values greater than reference, MRD should be a positive number and for values that are smaller, MRD should be negative. OUTCOMES: The severe pneumonia observed in SARS-CoV-2/HIV-1-positive patient under protease inhibitors was reversed by a 7-days hydroxychloroquine therapy. At the end of treatment, on day 7, patient reported resolution of fever, normalization of respiratory rate (14 breaths/min), and improved oxygen arterial pressure with a FiO2 of 30%. MRD values for IFNα/β and CD4 and CD8 T cells expressing CD38 and/or HLA-DR found in SARS-CoV-2-/HIV-1-coinfected woman were approximatively equal to 0 when refereed respectively to HIV-1-positive female patients [MRDs IFNα/β: median -0.2545 (range: -0.5/0.1); T cells: median -0.11 (range: -0.8/1.3)] and ≥ 6 when referred to healthy individuals [MRDs IFNα/β: median 28.45 (range: 15/41.9); T cells: median 10 (range 6/22)]. LESSONS: These results indicate that SARS-CoV-2 infection in HIV-1-positive female patient was associated with increased levels of IFNα/β-mRNAs and T cell activation compared to healthy individuals.

Indexed as

Anti-Retroviral AgentsBetacoronavirusCase-Control StudiesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCoronavirus InfectionsCOVID-19Enzyme InhibitorsFemaleHIV InfectionsHumansHydroxychloroquineInterferonsLymphocyte ActivationMiddle AgedPandemicsAnti-Retroviral AgentsEnzyme InhibitorsHydroxychloroquineInterferonsRNA, Messenger

Identifiers

PMID32899009
PMCPMC7478511
OpenAlexW3081923608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.